Grant: Collaborative Health Research Projects (NSERC partnered)
University of Toronto
$230,549.00
Development of SPARC mimetic peptides for targeting peritoneal metastasis of epithelial ovarian cancer
EF 2010-11
Résumé
Approximately 2500 women in Canada are diagnosed with ovarian cancer each year and about 1700 of these women die of their disease. This high mortality rate is due to a lack of early detection and to the development of chemotherapy-resistant disease. Since most women present with advanced disease, there is a desperate need for more effective therapies targeting metastatic disease. The matrix surrounding cells plays a central role in promoting or inhibiting tumor progression. Our laboratory is interested in how proteins in the extracellular matrix regulate cell behaviours. A prime focus of my laboratory is a small mobile extracellular matrix protein called SPARC. Studies have indicated that SPARC serves as a tumor suppressor and impedes metastasis of ovarian cancer. Work in my laboratory on model organisms supports a role for SPARC in stopping cell proliferation and migration. Moreover, I have found that a small part of the SPARC protein (peptide 4.2) can elicit these effects. My lab has joined with two molecular biology and one protein biochemistry laboratories working in ovarian cancer to test the ability of this small peptide to inhibit ovarian cancer progression. We will develop stable analogues of peptide 4.2 with enhanced biological function, which we will test using a variety of cell line models. We will also use a powerful mouse model of ovarian cancer to test the efficacy of promising analogues to inhibit cancer progression. This work will establish the potential of these analogues for further development as therapeutics in the treatment of advanced ovarian cancer.
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
222872
Name
Ringuette Maurice J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Development of SPARC mimetic peptides for targeting peritoneal metastasis of epithelial ovarian cancer
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$230,549
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Epithelial Ovarian Cancer
Abstract
Approximately 2500 women in Canada are diagnosed with ovarian cancer each year and about 1700 of these women die of their disease. This high mortality rate is due to a lack of early detection and to the development of chemotherapy-resistant disease. Since most women present with advanced disease, there is a desperate need for more effective therapies targeting metastatic disease. The matrix surrounding cells plays a central role in promoting or inhibiting tumor progression. Our laboratory is interested in how proteins in the extracellular matrix regulate cell behaviours. A prime focus of my laboratory is a small mobile extracellular matrix protein called SPARC. Studies have indicated that SPARC serves as a tumor suppressor and impedes metastasis of ovarian cancer. Work in my laboratory on model organisms supports a role for SPARC in stopping cell proliferation and migration. Moreover, I have found that a small part of the SPARC protein (peptide 4.2) can elicit these effects. My lab has joined with two molecular biology and one protein biochemistry laboratories working in ovarian cancer to test the ability of this small peptide to inhibit ovarian cancer progression. We will develop stable analogues of peptide 4.2 with enhanced biological function, which we will test using a variety of cell line models. We will also use a powerful mouse model of ovarian cancer to test the efficacy of promising analogues to inhibit cancer progression. This work will establish the potential of these analogues for further development as therapeutics in the treatment of advanced ovarian cancer.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ringuette, Maurice J
Approvedterm
3 ans 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $230,549~ $0~